Intellia Therapeutics, Inc.NTLANASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank73
3Y CAGR-0.7%
5Y CAGR+62.0%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-0.7%/yr
vs +42.7%/yr prior
5Y CAGR
+62.0%/yr
Recent deceleration
Acceleration
-43.3pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
11.2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $492.74M | -15.3% |
| 2024 | $581.86M | +7.2% |
| 2023 | $542.59M | +7.9% |
| 2022 | $502.71M | +71.0% |
| 2021 | $294.01M | +565.7% |
| 2020 | $44.17M | +7.6% |
| 2019 | $41.06M | -66.2% |
| 2018 | $121.30M | +26.8% |
| 2017 | $95.67M | +96.7% |
| 2016 | $48.64M | - |